Each day we come into work focused on one thing: advancing potential treatments for patients in need.
Today, patients all over the world are participating in our clinical studies.
Explore Programs
Biliary tract cancers are rare tumors that affect the bile ducts inside and outside the liver (cholangiocarcioma) or the gall bladder (gall bladder cancer).
Biliary tract cancers are rare tumors that affect the bile ducts inside and outside the liver (cholangiocarcioma) or the gall bladder (gall bladder cancer). Each year, over 12,000 people in the United States are diagnosed with cholangiocarcinoma or gall bladder cancer1,2. The rate of biliary tract cancers is higher in South Asia and South America3. Today’s standard treatments for biliary tract cancer are surgery, radiation and chemotherapy4,5. Zymeworks is currently conducting clinical trials to test new potential targeted treatments for this disease.
1American Cancer Society: Key Statistics for Bile Duct Cancer
2 American Cancer Society: Key Statistics for Gall Bladder Cancer
3 Bridgewater JA et al. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol (ASCO) Educ Book. 2016; 35: e194-203.
4 NIH National Cancer Institute: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ)–Patient Version
5 NIH National Cancer Institute: Gall Bladder Cancer Treatment (PDQ)–Patient Version
Zanidatamab is a bispecific antibody therapy for the treatment of patients with HER2-expressing cancers
A Global Phase 2 Registration-Enabling Trial Evaluating Single Agent Zanidatamab (ZW25) in Patients With Previously Treated HER2 Gene Amplified Biliary Tract Cancer
Clinical Trial Info
ZW49 is a bispecific antibody drug conjugate (ADC) therapy for the treatment of patients with HER2-expressing cancers.
A Dose Finding Phase 1 Study of ZW49 in Patients With HER2-Positive Cancers
Clinical Trial Info
Breast cancer occurs when cells of the breast grow uncontrollably.
Breast cancer is a type of cancer that occurs when cells of the breast grow uncontrollably. Globally, breast cancer is the most common cancer in women, affecting 2.1 million women each year. Rates are increasing in nearly every region of the world1. About 15 to 20 percent of all breast cancers are positive for human epidermal growth factor receptor 2, or HER2, which means they make too much of this protein2. Too much HER2 protein may cause cancer to grow more quickly and spread to other parts of the body3. Today’s standard treatments for breast cancer include surgery, radiation, chemotherapy, hormone therapy, targeted therapy, and immunotherapy4. Zymeworks is currently conducting clinical trials to test new potential targeted treatments for this disease.
1 World Health Organization Breast Cancer
2 NIH National Cancer Institute SEER Progrm: Cancer Stat Facts: Female Breast Cancer Subtypes
3 NIH National Cancer Institute: NCI Dictionary of Cancer Terms
4 NIH National Cancer Institute: Breast Cancer Treatment (Adult) (PDQ)–Patient Version
Zanidatamab is a bispecific antibody therapy for the treatment of patients with HER2-expressing cancers
ZW49 is a bispecific antibody drug conjugate (ADC) therapy for the treatment of patients with HER2-expressing cancers.
A Dose Finding Phase 1 Study of ZW49 in Patients With HER2-Positive Cancers
Clinical Trial Info
Gastroesophageal adenocarcinomas (GEAs) are cancers that begin in the stomach (gastric) and gastroesophageal junction.
Gastroesophageal adenocarcinomas (GEAs) are cancers that begin in the stomach (gastric) and gastroesophageal junction. Stomach cancer is the fifth most common malignancy worldwide with over a million new cases per year1. GEAs are approximately 20 times more prevalent in Eastern Asia than in North America. Nearly 18 percent of GEAs are positive for human epidermal growth factor receptor 2, or HER2, which means they make too much of this protein2. Too much HER2 protein may cause cancer to grow more quickly and spread to other parts of the body3. Today’s standard treatments for GEAs include surgery, radiation, chemotherapy, targeted therapy, and immunotherapy4. Zymeworks is currently conducting clinical trials to test new potential targeted treatments for this disease.
1 World Health Organization GLOBOCAN 2018 Stomach Fact Sheet
2 Custem EV et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015; 18:476–484.
3 NIH National Cancer Institute: NCI Dictionary of Cancer Terms
4 NIH National Cancer Institute: Gastric Cancer Treatment (PDQ®)–Patient Version
Zanidatamab is a bispecific antibody therapy for the treatment of patients with HER2-expressing cancers
A Safety and Efficacy Phase 2 Study of Zanidatamab (ZW25) Plus Combination Chemotherapy in HER2-Expressing Gastroesophageal Adenocarcinoma
Clinical Trial Info
ZW49 is a bispecific antibody drug conjugate (ADC) therapy for the treatment of patients with HER2-expressing cancers.
A Dose Finding Phase 1 Study of ZW49 in Patients With HER2-Positive Cancers
Clinical Trial Info
Other types of cancers also express too much human epidermal growth factor receptor 2, or HER2, a protein normally involved in cell growth. These cancers may include stomach, colorectal, ovarian, endometrial, cervical, lung, bladder, and pancreatic cancers. Too much HER2 protein may cause cancer to grow more quickly and spread to other parts of the body1. Standard treatments for HER2-expressing cancers vary depending on the type of cancer, and often include surgery, radiation, and chemotherapy. Zymeworks is currently conducting clinical trials to test new potential targeted treatments for these diseases.
1 NIH National Cancer Institute: NCI Dictionary of Cancer Terms
Zanidatamab is a bispecific antibody therapy for the treatment of patients with HER2-expressing cancers
ZW49 is a bispecific antibody drug conjugate (ADC) therapy for the treatment of patients with HER2-expressing cancers.
A Dose Finding Phase 1 Study of ZW49 in Patients With HER2-Positive Cancers
Clinical Trial Info
Clinical trials are scientific studies, conducted by doctors, to determine how well a new treatment works and if it has any side effects in people. The goal is to help people by finding better ways to prevent, screen for, diagnose, or treat disease. People can participate in clinical trials as patients or healthy volunteers1.
Clinical trials are the final step in a long process, which typically takes over a decade and begins with discoveries made in a research laboratory2. All approved medicines have been tested in clinical trials and are regulated by health authorities, such as the Food and Drug Administration (FDA) and European Medical Agency (EMA).
To participate in a clinical trial, please contact your doctor.
For more information about clinical trials, visit the National Institutes for Health Clinical Trials website.
1FDA - Clinical Research Versus Medical Treatment
2FDA - Learn About Drug and Device Approvals